The Global Antibody-Drug Conjugates Market - Forecasts from 2019 to 2024

September 2019 | 98 pages | ID: G2C866868885EN
Knowledge Sourcing Intelligence LLP

Abstracts

The global antibody-drug conjugates (ADCs) market is expected to reach $11,062.460 million by 2024 from $2,704.460 million in 2018, at a CAGR of 26.46%. Antibody-drug conjugates consist of a monoclonal antibody (mAb), a cytotoxic drug and a linker. These ADCs help in providing selectivity where it is able to select a tumor from a normal cell, hence provides effective therapy for targeted cancer treatment, promoting the market growth during the forecast period. The major drivers attributed to the market growth comprises of growing health expenditure which includes spending on cancer care, growing extensive research activities on ADCs worldwide, and a growing trend towards targeted cancer therapeutics with the growing cancer incidences worldwide. At present, only four ADCs have received market approval, and many are at different stages of development. Furthermore, big companies are also collaborating with each other and/or with the research and academic organizations for the development of ADCs, further promoting market growth during the forecast period.

The Global Antibody-Drug Conjugates Market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target, by indication, and by geography.

The global antibody-drug conjugates market on segmented based on target, indication, and geography. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.

Regional analysis has been provided with detailed analysis and forecast for the period 2018 to 2024, taking 2018 as the base year. The global market has been broken down into North America, South America, Europe, Middle East and Africa, and the Asia Pacific regions. The report also analyzes 14 major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.

Major players in the global antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the global antibody-drug conjugates market.

Segmentation

The global antibody-drug conjugates market has been analyzed through the following segments:

• By Target
• CD 30
• CD 22
• HER 2
• By Indication
• Haematologic Malignancies
• Non-Haematologic Malignancies
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Australia
• Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET BY TARGET

5.1. CD
5.2. CD
5.3. HER

6. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION

6.1. Haematologic Malignancies
6.2. Non-Haematologic Malignancies

7. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET BY GEOGRAPHY

7.1. North America
  7.1.1. USA
  7.1.2. Canada
  7.1.3. Mexico
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. United Kingdom
  7.3.2. Germany
  7.3.3. France
  7.3.4. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. UAE
  7.4.3. Israel
  7.4.4. Others
7.5. Asia Pacific
  7.5.1. China
  7.5.2. India
  7.5.3. Australia
  7.5.4. Others

8. COMPETITIVE INTELLIGENCE

8.1. Market Positioning Matrix and Ranking
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Takeda Pharmaceutical Company Limited
9.2. F. Hoffmann-La Roche Ltd.
9.3. ImmunoGen Inc.
9.4. Pfizer Inc.
9.5. Lonza
9.6. Synthon Holding B.V.
9.7. Immunomedics
9.8. Biotest AG
9.9. Astellas Pharma Inc.
9.10. Seattle Genetics, Inc.